Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety monitoring of Anlotinib Hydrochloride Capsules (Fu Kewei)
ChiCTR2100044367Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), soft tissue sarcoma (STS), thyroid cancer and 1 more, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: Adverse events during anlotinib treatment and Serious adverse events during anlotinib treatment. Started Jan 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)soft tissue sarcoma (STS)thyroid cancerNonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2100044367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044367.